NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.14 -0.04 (-1.83 %)
(As of 07/22/2018 08:48 AM ET)
Previous Close$2.14
Today's Range$2.08 - $2.22
52-Week Range$1.86 - $4.24
Volume3.05 million shs
Average Volume4.08 million shs
Market Capitalization$254.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51
AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960

Debt

Debt-to-Equity Ratio-0.36
Current Ratio1.34
Quick Ratio1.34

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.58 million
Price / Sales33.59
Cash FlowN/A
Price / CashN/A
Book Value($0.34) per share
Price / Book-6.29

Profitability

EPS (Most Recent Fiscal Year)($0.16)
Net Income$-65,020,000.00
Net Margins-1,073.16%
Return on EquityN/A
Return on Assets-39.88%

Miscellaneous

Employees19
Outstanding Shares118,990,000
Market Cap$254.64

AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.00. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.98 million. View AVEO Pharmaceuticals' Earnings History.

What price target have analysts set for AVEO?

3 brokerages have issued 1 year target prices for AVEO Pharmaceuticals' shares. Their forecasts range from $4.50 to $5.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 122.0% from the stock's current price. View Analyst Ratings for AVEO Pharmaceuticals.

What is the consensus analysts' recommendation for AVEO Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a increase in short interest in June. As of June 29th, there was short interest totalling 14,384,951 shares, an increase of 62.6% from the June 15th total of 8,846,865 shares. Based on an average daily volume of 3,238,387 shares, the days-to-cover ratio is currently 4.4 days. Currently, 15.0% of the company's shares are sold short. View AVEO Pharmaceuticals' Current Options Chain.

Who are some of AVEO Pharmaceuticals' key competitors?

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael P. Bailey, CEO, Pres & Director (Age 53)
  • Mr. Matthew D. Dallas, Chief Financial Officer (Age 43)
  • Dr. Michael N. Needle, Chief Medical Officer (Age 58)
  • Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 59)
  • Dr. Emile Farhan Ph.D., VP of Technical Operations

Has AVEO Pharmaceuticals been receiving favorable news coverage?

News stories about AVEO stock have been trending somewhat positive this week, Accern reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a news impact score of 0.18 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.92 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Creative Planning (0.05%). Company insiders that own AVEO Pharmaceuticals stock include Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.

Which institutional investors are buying AVEO Pharmaceuticals stock?

AVEO stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $2.14.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $254.64 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]


MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  253 (Vote Outperform)
Underperform Votes:  243 (Vote Underperform)
Total Votes:  496
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.